Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab)

被引：63
|
作者：
Leonard, JP
Link, BK
机构：
[1] Cornell Univ, Weill Med Coll, Ctr Lymphoma & Myeloma, New York, NY 10021 USA
[2] Cornell Univ, Weill Med Coll, Div Hematol Oncol, New York, NY 10021 USA
[3] New York Presbyterian Hosp, New York, NY USA
[4] Univ Iowa, Coll Med, Holden Comprehens Canc Ctr, Iowa City, IA USA
[5] Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA
来源：
SEMINARS IN ONCOLOGY | 2002年 / 29卷 / 01期
关键词：
D O I：
10.1053/sonc.2002.30149
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：81 / 86
页数：6
相关论文
共 50 条
  • [1] Epratuzumab (hLL2, anti-CD22 humanized monoclonal antibody) is an active and well-tolerated therapy for refractory/relapsed diffuse large B-cell non-Hodgkin's lymphoma (NHL).
    Leonard, JP
    Coleman, M
    Chadburn, A
    Matthews, JC
    Bayer, RL
    Schuster, MW
    Feldman, EJ
    Juweid, M
    Schuster, SJ
    Wegener, WA
    Goldenberg, DM
    BLOOD, 2000, 96 (11) : 578A - +
  • [2] Phase I/II trial epratuzumab (humanized anti-CD22 antibody) in non-Hodgkin's lymphoma (NHL).
    Leonard, JP
    Coleman, M
    Matthews, JC
    Chadburn, A
    Wegener, WA
    Hansen, HJ
    Ziccardi, H
    Kapushoc, H
    Gayko, U
    Cesano, A
    Fields, SZ
    Goldenberg, DM
    BLOOD, 2002, 100 (11) : 358A - 358A
  • [3] Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma
    Leonard, JP
    Coleman, M
    Ketas, JC
    Chadburn, A
    Ely, S
    Furman, RR
    Wegener, WA
    Hansen, HJ
    Ziccardi, H
    Eschenberg, M
    Gayko, U
    Cesano, A
    Goldenberg, DM
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) : 3051 - 3059
  • [4] Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma
    Strauss, Sandra J.
    Morschhauser, Frank
    Rech, Juergen
    Repp, Roland
    Solal-Celigny, Philippe
    Zinzani, Pier L.
    Engert, Andreas
    Coiffier, Bernard
    Hoelzer, Dieter F.
    Wegener, William A.
    Teoh, Nick K. W.
    Goldenberg, David M.
    Lister, T. Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) : 3880 - 3886
  • [5] Epratuzumab, a new anti-CD22, humanized, monoclonal antibody for the therapy of non-Hodgkin's lymphoma (NHL): Phase I/II trial results.
    Leonard, JP
    Coleman, M
    Schuster, MW
    Chadburn, A
    Ely, S
    Yagan, N
    Sharkey, RM
    Hansen, HJ
    Goldenberg, DM
    BLOOD, 1999, 94 (10) : 92A - 93A
  • [6] Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results
    Leonard, JP
    Coleman, M
    Ketas, JC
    Chadburn, A
    Furman, R
    Schuster, MW
    Feldman, EJ
    Ashe, M
    Schuster, SJ
    Wegener, WA
    Hansen, HJ
    Ziccardi, H
    Eschenberg, M
    Gayko, U
    Fields, SZ
    Cesano, A
    Goldenberg, DM
    CLINICAL CANCER RESEARCH, 2004, 10 (16) : 5327 - 5334
  • [7] Comparison of tumor targeting with 111In-labeled humanized anti-CD22 (111In hLL2) monoclonal antibody (MAB) scanning and 18FDG-PET in patients with relapsed non-Hodgkin's lymphoma.
    Matthies, A
    Cortés-Blanco, A
    Juweid, M
    Pourdehnad, M
    Goldenberg, DM
    Alavi, AA
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 276P - 276P
  • [8] Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma
    Stein, R
    Qu, ZX
    Chen, S
    Rosario, A
    Shi, V
    Hayes, M
    Horak, ID
    Hansen, HJ
    Goldenberg, DM
    CLINICAL CANCER RESEARCH, 2004, 10 (08) : 2868 - 2878
  • [9] Preclinical activity of hLL2-PBD, a novel anti-CD22 antibody-pyrrolobenzodiazepine (PBD) conjugate in models of non-Hodgkin lymphoma
    Zammarchi, Francesca
    Williams, David
    Havenith, Karin
    D'Hooge, Francois
    Howard, Philip W.
    Hartley, John A.
    van Berkel, Patrick
    CANCER RESEARCH, 2015, 75
  • [10] Phase I/II radioimmunotherapy trial with 90Y-labeled epratuzumab (LymphoCide™ anti-CD22 monoclonal antibody) in relapsed/refractory non-Hodgkin's lymphoma (NHL).
    Hajjar, G
    Burton, JD
    Sharkey, RM
    Schuster, SL
    Czuczman, M
    Lamonica, D
    Chatal, JF
    Alavi, A
    Stadtmauer, E
    Leonard, JP
    Coleman, M
    Goldenberg, DM
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 156P - 156P
12345